Sucralfate

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022
Health, Pharmaceutical, Proton, Joint Medical Service (Germany), Reckitt, Constipation, Irritable bowel syndrome, Population, Ageing, Antiemetic, Daiichi Sankyo, Ulcerative colitis, Rockies Express Pipeline, Degenerative disease, Sucralfate, Proton-pump inhibitor, Antibody, Diverticular disease, Bayer, Route of administration, COVID-19, Prescription drug purchasing pool, Patent, Johnson & Johnson, Inflammatory bowel disease, Peptide, Procter & Gamble, WHO, Anal fissure, Hemorrhoid, Antacid, Heartburn, Organization, Eli Lilly, Takeda Pharmaceutical Company, Proton pump, Protein, Antidiarrhoeal, CAGR, Growth, Abbott Laboratories, Gastrointestinal tract, Fine chemical, Dietary supplement, Pharmaceutical industry, Misoprostol

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Alaskan Puppy Poisoned by Hand Warmer Packet

Retrieved on: 
Wednesday, November 3, 2021
Decontamination, Milk, Freezing, Omeprazole, Pet emergency management, Shock, DABT, Poisoning, Stomach, Smith, PETS, Dog, Liver injury, Hand, GiFT, MS, Mark (given name), Sucralfate, Vomiting, Extrapyramidal system, Toxicology, Emergency, Bird, Iron, Magnesium hydroxide, Absorption, GI, Buoy, Veterinarian, DVM, Cat, Parent, Animal, Medical imaging

What many people don't realize, including pet lovers, is that many hand warmers contain iron and can be highly toxic to pets.

Key Points: 
  • What many people don't realize, including pet lovers, is that many hand warmers contain iron and can be highly toxic to pets.
  • It was late November 2020, and the Smith family had recently welcomed their new puppy Buoy into their home.
  • "The kids came in and asked for help opening their hand warmer packages.
  • It looked like black tar, but we could see remnants of the hand warmer package paper.

Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

Retrieved on: 
Monday, January 27, 2020
Pharmaceutical industry, Pharmaceuticals policy, Health, Mergers and acquisitions, Articles, Endo International plc, Allergan, Authorized generics, Sucralfate, Generic drug

DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.

Key Points: 
  • DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.
  • "Par is proud to partner with Allergan to bring the authorized generic of Carafate to patients," saidDomenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics atEndo.
  • "We are pleased to add this product to our portfolio and continue Par's tradition of being a reliable, quality supplier."
  • According to IQVIA data, U.S market annual sales for the 12 months ended November 30, 2019, for sucralfate oral suspension was estimated to be approximately $285 million.

Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States

Retrieved on: 
Monday, January 27, 2020
Pharmaceutical industry, Pharmaceuticals policy, Health, Mergers and acquisitions, Articles, Endo International plc, Allergan, Authorized generics, Sucralfate, Generic drug

DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.

Key Points: 
  • DUBLIN, Jan. 27, 2020 /PRNewswire/ --Endo International plc(NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan's Carafate (sucralfate) oral suspension 1gm/10 mL.
  • "Par is proud to partner with Allergan to bring the authorized generic of Carafate to patients," saidDomenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics atEndo.
  • "We are pleased to add this product to our portfolio and continue Par's tradition of being a reliable, quality supplier."
  • According to IQVIA data, U.S market annual sales for the 12 months ended November 30, 2019, for sucralfate oral suspension was estimated to be approximately $285 million.

U.S. Sucralfate Market to Surpass US$ 388.2 Million by 2026 – Coherent Market Insights

Retrieved on: 
Monday, August 26, 2019
Medical devices, Clinical trials, Biotechnology, Managed care, Pharmaceutical, Health, General Health, Health, Pharmaceutical companies, RTT, Science and technology in Israel, Teva Pharmaceutical Industries, Allergan, Pharmaceutical industry, Sucralfate, Helicobacter pylori

According to Coherent Market Insights, the U.S. sucralfate market was valued at US$ 296.2 million in 2017, and is projected to exhibit a CAGR of 3.1% over the forecast period (20182026).

Key Points: 
  • According to Coherent Market Insights, the U.S. sucralfate market was valued at US$ 296.2 million in 2017, and is projected to exhibit a CAGR of 3.1% over the forecast period (20182026).
  • Key Trends and Analysis of the U.S. Sucralfate Market:
    Key trends in market are increasing prevalence of gastrointestinal disorders and H. pylori-associated infections and increasing research and development activities by market players.
  • Furthermore, increasing research and development activities is expected to drive the U.S. sucralfate market growth.
  • Key players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc.
    To know the latest trends and insights prevalent in this market, click the link below: